Weekly electronic symptom tracking during definitive chemoradiotherapy for lung cancer
A Prospective Observational Study on Symptom Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
This project will test whether weekly electronic questionnaires can map symptom severity and clusters in adults with unresectable stage III non-small cell or limited-stage small cell lung cancer receiving definitive concurrent chemoradiotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tongji Hospital Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT07131670 on ClinicalTrials.gov |
What this trial studies
This prospective observational project enrolls adults with unresectable stage III NSCLC or limited-stage SCLC who are receiving definitive concurrent chemoradiotherapy and can complete electronic questionnaires. Participants complete the validated MDASI-LC and EQ-5D weekly from baseline through the end of CRT and for 12 weeks after treatment to capture symptom severity and interference over time. The study will use longitudinal analyses to characterize symptom trajectories, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of high symptom burden. Findings are intended to inform personalized symptom-management strategies and improve quality of life during and after CRT.
Who should consider this trial
Good fit: Adults (≥18 years) with pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC who are scheduled to receive definitive concurrent chemoradiotherapy, can complete electronic questionnaires, and can give written informed consent.
Not a fit: Patients with severe heart, liver, or kidney comorbidities, significant psychiatric or cognitive impairment, or prior chest/mediastinal radiotherapy are excluded and unlikely to benefit.
Why it matters
Potential benefit: If successful, this could enable more personalized symptom management that reduces symptom burden and improves quality of life during and after chemoradiotherapy.
How similar studies have performed: Electronic patient-reported outcome programs and MDASI-based monitoring have previously shown promise in oncology for detecting symptoms and guiding care, but longitudinal symptom-cluster analysis specifically in definitive CRT populations is relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC * Age ≥ 18 years * Receiving definitive chemoradiotherapy * Able and willing to complete electronic questionnaires * Provided written informed consent Exclusion Criteria: * Severe comorbidities (heart, liver, kidney) * Psychiatric illness or cognitive impairment * Prior chest or mediastinal radiotherapy
Where this trial is running
Wuhan, Hubei
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.